Ali Al Khayru
Interventional Cardiology · Sparks, NVNPI 1780115923
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.7%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abbott at 41.5% of the total. Reporting peaked in 2023 at $5,375 and has fallen 88.6% since, to $611 in 2025.
Across 118 payments — averaging $92.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$1K
- Terumo Medical Corporation$928
- Medtronic$877
- Abiomed$702
- Cardiovascular Systems Inc.$537
- plus $2K from 15 others
What the payments were for
- Grants$1,06310%
- Travel & lodging$3,31330%
- Food & beverage$6,18157%
- Education$3403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $4,526 |
| Boston Scientific | 4 | $1,296 |
| Terumo Medical Corporation | 10 | $928 |
| Medtronic | 10 | $877 |
| Abiomed | 5 | $702 |
| Cardiovascular Systems Inc. | 9 | $537 |
| Cordis US CORP. | 3 | $336 |
| Inari Medical, Inc. | 2 | $199 |
| Amgen | 3 | $193 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $188 |
| Johnson & Johnson | 7 | $177 |
| Chiesi USA, Inc. | 2 | $167 |
| Reflow Medical Inc | 3 | $166 |
| Atricure, Inc. | 1 | $152 |
| Actelion Pharmaceuticals US, Inc. | 1 | $127 |
| Pfizer | 2 | $106 |
| Shockwave Medical, Inc | 4 | $90 |
| Cook Medical LLC | 1 | $49 |
| Penumbra, Inc. | 1 | $48 |
| Boehringer Ingelheim | 1 | $19 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERA$1,803
- Diamondback Coronary$855
- GLIDESHEATH SLENDER$470
- Impella$454
- Diamondback Peripheral$294
- ONYX FRONTIER$277
- Confirm Rx$252
- CARDIOMEMS$181
- ENSITE$178
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$169
- Micra$163
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$152
- RADIAL 360$150
- WATCHMAN Access System$142
- CT THROMBECTOMY SYSTEM KIT$135
- FLOWTRIEVER CATHETER, S$135
- MYNXGRIP$133
- Telescope$128
- UPTRAVI$127
- OPSUMIT$127
How this compares
$10,897 in reported general payments places this provider in the 55th percentile of 62 interventional cardiology providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 35 | $457 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Sparks
- Carl JuneauSparks$11K
- Eric DrummerSparks$9K
- Thomas TruongSparks$8K
- Cres MirandaLas Vegas$660K
- Jeffrey LevismanHenderson$226K
- Howard BroderHenderson$168K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Karthiek NaralaHenderson$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.